FDA Approves Dupilumab For Atopic Dermatitis

shutterstock_241896847

Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist.

Dupixent is specifically indicated for the treatment of moderate-to-severe atopic dermatitis in adults, where disease is not adequately controlled by topical prescription therapies or in conditions when those therapies are not advisable for the patient.

Dupixent is used as a solution for subcutaneous administration. The recommended dose of Dupixent for adults is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week. It can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used with it, but should be reserved for problem areas like, such as the face, neck, intertriginous and genital areas. If a dose is missed, the injection should be administered within 7 days from the missed dose and then the original schedule should be resumed. If the missed dose is not administered within 7 days, the patient should wait until the next dose on the original schedule.

OmniMD has you completely covered.

OmniMD EHR, Revenue Cycle Management (RCM) and Medical Billing service have helped over 12,000 healthcare professionals improve their clinical operations, patient care, and collections.
 
Let us help you take back your practice, patients, profits and maximize your revenues.

Add a Comment